-
Unravelling the Causal Relationship between Endometriosis and the Risk for Developing Venous Thromboembolism: A Pooled Analysis Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-18 Pauline De Corte, Igor Milhoranca, Sylvia Mechsner, Anna Sara Oberg, Tobias Kurth, Klaas Heinemann
Objective To investigate the effect of endometriosis on venous thromboembolism (VTE) in oral contraceptive (OC) users. Pooled analysis on a harmonized dataset compromising international patient-centric cohort studies: INAS-VIPOS, INAS-SCORE, and INAS-FOCUS. Eleven European countries, the United States, and Canada. Individuals being newly prescribed an OC with or without an endometriosis and no VTE
-
Potential of Sulodexide in the Treatment of Diabetic Retinopathy and Retinal Vein Occlusion Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-18 Elsa Wilma Böhm, Francesco Buonfiglio, Christina A. Korb, Alice Dauth, Norbert Pfeiffer, Andrzej Bręborowicz, Adrian Gericke
Retinal vascular diseases, such as diabetic retinopathy or retinal vein occlusion, are common causes of severe vision loss. Central to the pathophysiology of these conditions are endothelial dysfunction, inflammation, capillary leakage, ischemia, and pathological neoangiogenesis. Capillary damage leads to leakage and the development of macular edema, which is associated with vision loss and requires
-
Unraveling the Molecular Pathogenesis of Protein C Deficiency–Associated VTE: Insights from Protein C Mutations C238G and R189W in Thai Patients Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-18 Pansakorn Tanratana, Karnsasin Seanoon, Panwajee Payongsri, Praguywan Kadegasem, Ampaiwan Chuansumrit, Nongnuch Sirachainan
Background Protein C (PC) deficiency is a well-established risk factor for thromboembolism (TE), commonly manifesting in pediatric patients. This study aimed to elucidate the pathogenic mechanisms of two novel PC mutations, C238G and R189W, identified in Thai children with both venous and arterial TE. Material and Methods The effects of wild-type (WT), C238G, and R189W PC variants were investigated
-
Dynamics of Thrombogenicity and Platelet Function and Correlation with Bleeding Risk in Patients Undergoing M-TEER Using the PASCAL System Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-18 Miriam Euper, Jürgen Schreieck, Mareike Bladt, Monika Zdanyte, Andreas Goldschmied, Manuel Sigle, Dominick J. Angiolillo, Diana A. Gorog, Mia Ravn Jacobsen, Rikke Sørensen, Dominik Rath, Meinrad Gawaz, Tobias Geisler
Background Transcatheter mitral valve repair is performed in a patient population at risk for thrombotic and bleeding events. The effects on platelet function and reactivity and their association with bleeding events after mitral transcatheter edge-to-edge therapy (M-TEER) have not been systematically examined. Objectives We sought to investigate the association of different parameters of platelet
-
Time Trends and Excess Mortality Compared to Population Controls after a First-Time Pulmonary Embolism or Deep Vein Thrombosis Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-12 Katarina Glise Sandblad, Carl Johan Svensson, Kristina Svennerholm, Jacob Philipson, Aldina Pivodic, Sam Schulman, Mazdak Tavoly
Background Recent data on temporal trends in excess mortality for patients with pulmonary embolism (PE) and deep vein thrombosis (DVT) compared with the general population are scarce. Methods A nationwide Swedish register study conducted from 2006 to 2018 including 68,960 PE and 70,949 DVT cases matched with population controls. Poisson regression determined relative risk (RR) for 30-day and 1-year
-
A Phase 1b PK/PD Study to Demonstrate Antigen Elimination with RLYB212, a Monoclonal Anti-HPA-1a Antibody for FNAIT Prevention Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-12 Christof Geisen, Erika Fleck, Stephan Martin Gastón Schäfer, Carmen Walter, Susanne Braeuninger, Jens Søndergaard Jensen, Douglas Sheridan, Kiran Patki, Róisín Armstrong, Bjørn Skogen, Frank Behrens, Erhard Seifried, Jens Kjeldsen-Kragh, Mette Kjær, Michaela Köhm
Background Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare bleeding disorder of the fetus/newborn caused by development of maternal alloantibodies against fetal human platelet antigens (HPAs), predominantly HPA-1a. Currently there are no treatments available to prevent maternal alloimmunization to HPAs or FNAIT. Methods This proof-of-concept study (EudraCT Number: 2021-005380-49) was
-
Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-12 Midori Shima, Nobuaki Suzuki, Hidekazu Nishikii, Kagehiro Amano, Yoshiyuki Ogawa, Ryota Kobayashi, Ryoto Ozaki, Koichiro Yoneyama, Narumi Mizuno, Emiko Sakaida, Makoto Saito, Takashi Okamura, Toshihiro Ito, Norimichi Hattori, Satoshi Higasa, Yoshinobu Seki, Keiji Nogami
Background Primary analysis of the phase III AGEHA study suggested a favorable benefit–risk profile for emicizumab prophylaxis in patients with acquired hemophilia A (PwAHA); however, only patients undergoing immunosuppressive therapy (IST; Cohort 1) were included. Objectives To present final analysis results of AGEHA, including data on IST-ineligible patients (Cohort 2) and on long-term prophylaxis
-
Shear Stress Promotes Remodeling of Platelet Glycosylation via Upregulation of Platelet Glycosidase Activity: One More Thing Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-12 Yana Roka-Moiia, Sabrina Lewis, Estevan Cleveland, Joseph E. Italiano, Marvin J. Slepian
Background Mechanical circulatory support (MCS) is a mainstay of therapy for advanced and end-stage heart failure. Accompanied by systemic anticoagulation, contemporary MCS has become less thrombogenic, with bleeding complications emerging as a major cause of readmission and 1-year mortality. Shear-mediated platelet dysfunction and thrombocytopenia of undefined etiology are primary drivers of MCS-related
-
Emerging thrombotic disorders associated with virus-based innovative therapies: from VITT to AAV-gene therapy-related thrombotic microangiopathy. Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-11 Silvia Benemei,Francesca Gatto,Rossella Marcucci,Paolo Gresele
Gene therapy is a therapeutic approach for treating life-threatening disorders. Despite the clinical improvements observed with gene therapy, immune responses either innate or adaptive against the vector used for gene delivery can affect treatment efficacy and lead to adverse reactions. Thrombotic microangiopathy (TMA) is a thrombosis with thrombocytopenia syndrome (TTS) characterized by microangiopathic
-
Transfer RNAs are linked to ischemic stroke and major bleeding in patients with end-stage kidney disease. Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-11 Stephan Nopp,Oliver Königsbrügge,Sabine Schmaldienst,Marcus Säemann,Ingrid Pabinger,Anne Yaël Nossent,Cihan Ay
BACKGROUND Patients with end-stage kidney disease (ESKD) are at very high risk for thromboembolism and bleeding. This study aimed to identify small non-coding RNAs (sncRNAs), specifically microRNAs and transfer-RNA (tRNA)-derived fragments (tRFs), as potential novel biomarkers for predicting thromboembolism and bleeding in this high-risk population. METHODS In this sncRNA discovery research, we leveraged
-
Mepacrine flow cytometry assay for the diagnosis of platelet δ-granule defects : literature review on methods - towards a shared detailed protocol. Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-11 Mehdi Khourssaji,Marion Bareille,Lorenzo Alberio,Delphine Borgel,Marc Fouassier,Marie Christine Bene,Thomas Lecompte,François Mullier
Accurate assessment of platelet secretion is essential for the diagnosis of inherited or acquired platelet function disorders (PFDs) and more specifically in identifying δ-storage pool disease. Mepacrine, a fluorescent dye, specifically accumulates in platelet δ-granules. The mepacrine flow cytometry (FCM) assay has been used for more than half a century in the clinical laboratory as a diagnostic tool
-
The effect of increasing factor X levels on emicizumab-driven coagulation potential. Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-11 Ecaterina Scarlatescu
No Abstract.
-
Unfavorably altered fibrin clot phenotype in women following postpartum hemorrhage of unknown cause: effect of lower coagulation factors. Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-11 Magdalena Piróg,Michał Ząbczyk,Joanna Natorska,Elżbieta Broniatowska,Robert Jach,Anetta Undas
Background Increased clot permeability and susceptibility to lysis have been reported in women with heavy menstrual bleeding. We hypothesized that similarly altered fibrin clot properties in women with postpartum hemorrhage (PPH) of unknown cause. Objective To determine fibrin clot properties and their determinants in women after PPH of unknown cause. Methods We studied 52 consecutive women, aged 35
-
Elevated thrombin generation and VTE incidence in patients undergoing cytoreductive surgery with HIPEC compared with minimally invasive rectal surgery. Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-11 Mikkel Lundbech,Andreas Engel Krag,Lene Hjerrild Iversen,Birgitte Brandsborg,Nina Madsen,Anne-Mette Hvas
INTRODUCTION Surgical treatment of colorectal cancer carries a risk for venous thromboembolism (VTE). We investigated changes in coagulation and fibrinolysis and the VTE incidence within 30 days in patients undergoing open cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) for peritoneal metastases from colorectal cancer and minimally invasive surgery (MIS) for localized
-
Characteristics of bleeding complications in patients with severe COVID19 requiring veno-venous extracorporeal membrane oxygenation in Japan. Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-06 Hayato Taniguchi,Takeru Abe,Ichiro Takeuchi,Shinichiro Ohshimo,Nobuaki Shime,Shigeki Kushimoto,Satoru Hashimoto,Shinhiro Takeda
BACKGROUND Complications during veno-venous extracorporeal membrane oxygenation (VV-ECMO) are associated with in-hospital mortality. Asian patients on extracorporeal membrane oxygenation (ECMO) have a higher risk of bleeding and in-hospital mortality than Caucasian patients. This study aimed to characterise and identify bleeding complications and their associated factors related to in-hospital mortality
-
Reversible Thrombocytopenia of Functional Platelets after Nose-horned Viper Envenomation is Induced by a Snaclec. Thromb. Haemost. (IF 5.0) Pub Date : 2024-09-03 Mojca Dobaja Borak,Adrijana Leonardi,Kity Požek,Katarina Reberšek,Helena Podgornik,Aljaž Pirnat,Alenka Trampuš Bakija,Simona Kranjc Brezar,Tomaž Trobec,Monika C Žužek,Robert Frangež,Miran Brvar,Igor Križaj
Profound and transient thrombocytopenia of functional platelets without bleeding was observed in patients envenomed by Vipera a. ammodytes (Vaa). This condition was rapidly reversed by administration of F(ab)2 fragments of IgGs targeting the whole venom, leaving platelets fully functional. To investigate the potential role of snake venom C-type lectin-like proteins (snaclecs) in this process, Vaa-snaclecs
-
Volume Regulation and Nonosmotic Volume of Individual Human Platelets Quantified by High-Speed Scanning Ion Conductance Microscopy Thromb. Haemost. (IF 5.0) Pub Date : 2024-08-29 Konstantin Krutzke, Jan Seifert, Meinrad Gawaz, Johannes Rheinlaender, Tilman E. Schäffer
Background Platelets are anucleate cells that play an important role in wound closure following vessel injury. Maintaining a constant platelet volume is critical for platelet function. For example, water-induced swelling can promote procoagulant activity and initiate thrombosis. However, techniques for measuring changes in platelet volume such as light transmittance or impedance techniques have inherent
-
Handheld point-of-care devices for snakebite coagulopathy: a scoping review. Thromb. Haemost. (IF 5.0) Pub Date : 2024-08-30 Michael Abouyannis,Amy E Marriott,Emma Stars,Dianne P Kitchen,Steve Kitchen,Tim A L Woods,Benno Kreuels,John H Amuasi,Wuelton Marcelo Monteiro,Ymkje Stienstra,Subramanian Senthilkumaran,Geoffrey K Isbister,David G Lalloo,Stuart Ainsworth,Nicholas R Casewell
Venom induced consumption coagulopathy (VICC) is a common complication of snakebite that is associated with hypofibrinogenaemia, bleeding, disability, and death. In remote tropical settings, where most snakebites occur, the 20-minute whole blood clotting test is used to diagnose VICC. Point-of-care (POC) coagulation devices could provide an accessible means of detecting VICC that is better standardised
-
The Efficacy and Safety of DOACs in Inherited Antithrombin Deficiency: A Cohort Study from a Tertiary Referral Center Thromb. Haemost. (IF 5.0) Pub Date : 2024-08-21 Caroline Dix, Andrew J. Doyle, Karen Breen, Beverley J. Hunt
Background Individuals with inherited antithrombin deficiency (IATD) have a high risk of venous thromboembolism (VTE). Most VTEs are managed with direct oral anticoagulants (DOACs), but the utility of DOACs in antithrombin deficiency (ATD) is unreported. Materials and Methods Patients with IATD treated with DOAC were identified from our institutions' IATD registry. We assessed patients' characteristics
-
Venous Thromboembolism in Patients with Glioblastoma: Molecular Mechanisms and Clinical Implications Thromb. Haemost. (IF 5.0) Pub Date : 2024-08-21 Maaike Y. Kapteijn, Nina Bakker, Johan A. F. Koekkoek, Henri H. Versteeg, Jeroen T. Buijs
Patients with glioblastoma are among the cancer patients with the highest risk of developing venous thromboembolism (VTE). Long-term thromboprophylaxis is not generally prescribed because of the increased susceptibility of glioblastoma patients to intracranial hemorrhage. This review provides an overview of the current clinical standard for glioblastoma patients, as well as the molecular and genetic
-
Pneumococcal Neuraminidases Increase Platelet Killing by Pneumolysin Thromb. Haemost. (IF 5.0) Pub Date : 2024-08-20 Kristin J. Fritsch, Laura Krüger, Stefan Handtke, Thomas P. Kohler, Arina Ozhiganova, Kristin Jahn, Jan Wesche, Andreas Greinacher, Sven Hammerschmidt
Background Platelets prevent extravasation of capillary fluids into the pulmonary interstitial tissue by sealing gaps in inflamed endothelium. This reduces respiratory distress associated with pneumonia. Streptococcus pneumoniae is the leading cause of severe community-acquired pneumonia. Pneumococci produce pneumolysin (PLY), which forms pores in membranes of eukaryotic cells including platelets.
-
An Inhibitory Single-Domain Antibody against Protein Z-Dependent Protease Inhibitor Promotes Thrombin Generation in Severe Hemophilia A and FXI Deficiency Thromb. Haemost. (IF 5.0) Pub Date : 2024-08-12 Claire Auditeau, Tung-Son Nguyen, Floriane Devaux, François Saller, Ivan Peyron, Adeline Blandinières, Christelle Repérant, Sadyo Daramé, Cécile V. Denis, Peter Lenting, Delphine Borgel, Elsa P. Bianchini
Background Protein Z-dependent protease inhibitor (ZPI) is an anticoagulant serpin that targets factor Xa (FXa) in the presence of protein Z (PZ), and factor XIa (FXIa). In factor-VIII-deficient mice, PZ or ZPI gene knock-out mitigates the bleeding phenotype, and pharmacological inhibition of PZ enhances thrombin generation in plasma from patients with hemophilia. Aims To develop a single-domain antibody
-
Carbamylation Is Instrumental in End-Stage Kidney Disease Coagulopathies: The Impact on von Willebrand Factor and Platelet Functionality Thromb. Haemost. (IF 5.0) Pub Date : 2024-08-12 Janka Babickova, Urszula Kałucka, Alicja Sochaj-Grzegorczyk, Jan Potempa, Carsten Scavenius, Thomas Knoop, Hans-Peter Marti, Marta Kaminska, Piotr Mydel
Background Chronic kidney disease (CKD) is a progressive, irreversible, and incurable condition characterized by high morbidity and mortality, affecting approximately one-tenth of the global population. Rise of urea-derived cyanate levels in CKD patients, severalfold higher in comparison to those found in healthy individuals, leads to an increased rate of carbamylation of lysine residues of proteins
-
Harnessing risk assessment for thrombosis and bleeding to optimize anticoagulation strategy in nonvalvular atrial fibrillation. Thromb. Haemost. (IF 5.0) Pub Date : 2024-08-13 Yue Zhao,Li-Ya Cao,Ying-Xin Zhao,Di Zhao,Yi-Fan Huang,Fei Wang,Qian Wang
BACKGROUND Oral anticoagulation (OAC) following catheter ablation (CA) of nonvalvular atrial fibrillation (NVAF) is essential for the prevention of thrombosis events. Inappropriate application of OACs does not benefit thrombosis prevention but may be associated with a higher risk of bleeding. Therefore, this study aims to develop clinical data-driven machine learning (ML) methods to predict the risk
-
Shifting Priorities in the Prevention of Venous Thromboembolism: Time to Focus on Overall Cardiovascular Health. Thromb. Haemost. (IF 5.0) Pub Date : 2024-08-12 Stavros V Konstantinides
-
Serum Leucine Aminopeptidase Activity Patterns Across Various Disease States: Potential Implications for Bleeding and Thrombosis Risk Thromb. Haemost. (IF 5.0) Pub Date : 2024-08-06 Sha Yu, Meng Zhang, Yachong Guo, Lijuan Zhang
Background Disruptions in the pathways for activating and deactivating proteases in the bloodstream can lead to thrombosis and bleeding issues. Leucine aminopeptidases (LAPs), which are exopeptidases essential for regulating protein and peptide activities, are recognized as clinical biomarkers for liver diseases. However, the relationship between serum LAP activity and the risks of bleeding or thrombosis
-
Open Issues in the Choice and Management of Direct Oral Anticoagulants in Patients with Cancer-Related Venous Thromboembolism. Thromb. Haemost. (IF 5.0) Pub Date : 2024-08-06 Daniele Pastori,Gualtiero Palareti
-
Sensitivity to Aortic Rupture in Hereditary Aortic Diseases. Thromb. Haemost. (IF 5.0) Pub Date : 2024-08-31 Vivian de Waard
No abstract.
-
Educational Attainment, Obesity, and Venous Thromboembolism. Is Only Matter of Weight? Thromb. Haemost. (IF 5.0) Pub Date : 2024-08-01 Daniele Pastori,Angela Sciacqua
-
Timing of Off-Label Dosing of Direct Oral Anticoagulants in Three Large Health Systems Thromb. Haemost. (IF 5.0) Pub Date : 2024-07-30 Grace C. Herron, Deborah DeCamillo, Xiaowen Kong, Brian Haymart, Scott Kaatz, Stacy Ellsworth, Mona A. Ali, Christopher Giuliano, James B. Froehlich, Geoffrey D. Barnes
Background While direct oral anticoagulants (DOACs) may be viewed as simpler to manage then warfarin, they present their own unique management challenges resulting in frequent off-label dosing. It is unknown to what extent off-label dosing occurs when a patient is started on a DOAC versus later in their treatment. Objectives We aimed to better characterize when off-label DOAC dosing is occurring and
-
Venous Thromboembolism Post-allogeneic Hematopoietic Cell Transplant: Risk Factors, Incidence, and Outcomes Thromb. Haemost. (IF 5.0) Pub Date : 2024-07-30 Lauren M. Granat, Hong Li, Mariah Ondeck, Bennet Osantowski, Chana Peysin, Mailey Wilks, Christina Ferraro, Ronald Sobecks, Dana Angelini, Betty K. Hamilton
Background Venous thromboembolism (VTE) is a well-documented complication of both solid and hematologic malignancies, but there are fewer data on allogeneic hematopoietic cell transplant (HCT) recipients. Therefore, we studied the incidence, risk factors, and impact of VTE on post-HCT outcomes in a contemporary cohort. Methods We retrospectively reviewed patients who underwent allogeneic HCT between
-
Long-Term Safety of a Four-Factor Prothrombin Complex Concentrate (Kcentra®/Beriplex® P/N): An Updated Pharmacovigilance Review Thromb. Haemost. (IF 5.0) Pub Date : 2024-07-29 Truman J. Milling, Anna Voronov, Dirk S. Schmidt, Edelgard Lindhoff-Last
Introduction Four-factor prothrombin complex concentrate (4F-PCC) is recommended for vitamin K antagonist reversal in patients with major bleeding or in need of surgery. The most important risk associated with the use of 4F-PCC is the occurrence of thromboembolic events (TEEs). In this review, we aim to evaluate the safety profile of a 4F-PCC (Kcentra®/Beriplex® P/N; CSL Behring, Marburg, Germany)
-
Pulmonary Thromboembolism after Catheter Ablation of Cardiac Arrhythmias. Thromb. Haemost. (IF 5.0) Pub Date : 2024-07-16 Nebojsa Mujovic,Tatjana S Potpara
-
Development and Validation of a Nomogram for Predicting Sepsis-Induced Coagulopathy in Septic Patients: Mixed Retrospective and Prospective Cohort Study Thromb. Haemost. (IF 5.0) Pub Date : 2024-07-18 Yuting Li, Liying Zhang, Youquan Wang, Meng Gao, Chaoyang Zhang, Yuhan Zhang, Dong Zhang
Background Sepsis-induced coagulopathy (SIC) is a common cause of poor prognosis in critically ill patients in the intensive care unit (ICU). However, currently there are no tools specifically designed for predicting the occurrence of SIC in septic patients earlier. This study aimed to develop a predictive nomogram incorporating clinical markers and scoring systems to individually predict the probability
-
Binding Promiscuity of Therapeutic Factor VIII Thromb. Haemost. (IF 5.0) Pub Date : 2024-07-16 Alejandra Reyes Ruiz, Aishwarya S. Bhale, Krishnan Venkataraman, Jordan D. Dimitrov, Sébastien Lacroix-Desmazes
The binding promiscuity of proteins defines their ability to indiscriminately bind multiple unrelated molecules. Binding promiscuity is implicated, at least in part, in the off-target reactivity, nonspecific biodistribution, immunogenicity, and/or short half-life of potentially efficacious protein drugs, thus affecting their clinical use. In this review, we discuss the current evidence for the binding
-
Marginal Zone B Cells Represent a Conserved Initiating Player in the Immune Response to Factor VIII in Hemophilia A Mice. Thromb. Haemost. (IF 5.0) Pub Date : 2024-07-16 Maya Maarouf,Seema R Patel,Wallace Hunter Baldwin,Patricia E Zerra,Courtney Cox,Ernest T Parker,Sean R Stowell,Shannon L Meeks
-
Risk Factors, Antithrombotic Management, and Long-Term Outcomes of Patients Undergoing Endovascular Treatment of Unruptured Intracranial Aneurysms Thromb. Haemost. (IF 5.0) Pub Date : 2024-07-07 Yanxiao Xiang, Ping Zhang, Yongjie Lai, Donghai Wang, Anchang Liu
Background Patients receiving endovascular treatment for unruptured intracranial aneurysms (UIAs) face varying risks and benefits with antithrombotic management. This study aimed to evaluate the perioperative and long-term effects of antithrombotic strategies, identify the populations that would benefit, and explore the predictive factors affecting the long-term outcomes. Methods UIA patients undergoing
-
Monocyte Subsets in Cardiovascular Disease: A Biomarker Perspective Thromb. Haemost. (IF 5.0) Pub Date : 2024-07-06 Michael Hristov, Christian Weber
Endothelial dysfunctions together with a dysregulated immune response and lipid accumulation are important confounding factors in the onset and chronic development of atherosclerosis. Recently, a large body of data has emerged on the sequential involvement of different immune cell types, including monocytes, in the pathology of this disease. In this condensed review, we aim to highlight some of the
-
Risk of Major Bleeding with Antiplatelet and/or Anticoagulation Therapy in Inherited Factor XI Deficiency: Insights from Real-World Observations. Thromb. Haemost. (IF 5.0) Pub Date : 2024-07-04 Shanni Vaismann,Nili Stein,Liat Dizengoff,Amir Warwar,Shoshan Perek,Ibraheem Zoabi,Walid Saliba,Meir Preis
-
Novel Insights into the Aortic Mechanical Properties of Mice Modeling Hereditary Aortic Diseases Thromb. Haemost. (IF 5.0) Pub Date : 2024-07-01 Nicolo Dubacher, Kaori Sugiyama, Jeffrey D. Smith, Vanessa Nussbaumer, Máté Csonka, Szilamér Ferenczi, Krisztina J. Kovács, Sylvan M. Caspar, Lisa Lamberti, Janine Meienberg, Hiromi Yanagisawa, Mary B. Sheppard, Gabor Matyas
Objective Hereditary aortic diseases (hADs) increase the risk of aortic dissections and ruptures. Recently, we have established an objective approach to measure the rupture force of the murine aorta, thereby explaining the outcomes of clinical studies and assessing the added value of approved drugs in vascular Ehlers–Danlos syndrome (vEDS). Here, we applied our approach to six additional mouse hAD
-
Heterozygous Prothrombin Mutation-Associated Thrombophilia Thromb. Haemost. (IF 5.0) Pub Date : 2024-07-02 Xi Wu, Lei Li, Zhengjing Lu, Xiaobo Hu, Yeling Lu, Yu Liu, Guanqun Xu, Qiulan Ding, Xuefeng Wang, Wenman Wu, Peipei Jin, Jing Dai
Background Venous thromboembolism (VTE) is predisposed by thrombotic mutations in patients with hereditary thrombophilia. Although prothrombin deficiencies caused by homozygous or compound heterozygous mutations are associated with bleeding diathesis, rare cases have shown a correlation between heterozygous prothrombin mutations and thrombosis. Materials and Methods We surveyed genetic variants involved
-
2024 Chinese Expert Consensus Guidelines on the Diagnosis and Treatment of Atrial Fibrillation in the Elderly, Endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular branch): Executive Summary Thromb. Haemost. (IF 5.0) Pub Date : 2024-07-02 Yutang Wang, Yutao Guo, Mingzhao Qin, Jin Fan, Ming Tang, Xinjun Zhang, Hao Wang, Xiaoying Li, Gregory Y. H. Lip, Expert Reviewers
The consensus guidelines of the Geriatric Society of Chinese Medical Association on the management of atrial fibrillation (AF) in the elderly was first published in 2011 and updated in 2016, with endorsement by Chinese Society of Geriatric Health Medicine. Since then, many important studies regarding the screening and treatment in the elderly population have been reported, necessitating this updated
-
The LAT Rheostat as a Regulator of Megakaryocyte Activation Thromb. Haemost. (IF 5.0) Pub Date : 2024-06-14 Alyssa J. Moroi, Peter J. Newman
Background Specifically positioned negatively charged residues within the cytoplasmic domain of the adaptor protein, linker for the activation of T cells (LAT), have been shown to be important for efficient phosphorylation of tyrosine residues that function to recruit cytosolic proteins downstream of immunoreceptor tyrosine-based activation motif (ITAM) receptor signaling. LAT tyrosine 132—the binding
-
Circulating Blood Biomarkers and Risk of Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis Thromb. Haemost. (IF 5.0) Pub Date : 2024-06-12 Danielle Carole Roy, Tzu-Fei Wang, Ronda Lun, Amin Zahrai, Ranjeeta Mallick, Dylan Burger, Gabriele Zitikyte, Steven Hawken, Philip Wells
Background Cancer patients have an increased risk of venous thromboembolism (VTE). Currently, the availability of highly discriminatory prediction models for VTE in cancer patients is limited. The implementation of biomarkers in prediction models might lead to refined VTE risk prediction. In this systematic review and meta-analysis, we aimed to evaluate candidate biomarkers and their association with
-
Prethrombin-1 as a Drug Substance Promoting Hemostasis with Reduced Risk of Thrombosis Thromb. Haemost. (IF 5.0) Pub Date : 2024-06-12 Johann Georg Graus, Michael Prückler, Helga Bergmeister, Christoph Mader, Alexandru Trefilov, Richard Gölles, Marianne Kunschak, Wolfgang Schramm
Introduction Prethrombin-1 is a Gla-domain lacking enzymatically inactive split product that results from the cleavage of fragment 1 from prothrombin by thrombin in a feedback reaction. Methods A prethrombin-1 preparation derived from human plasma was tested for its hemostatic and thrombogenic properties. Animal models of nail clipping (for rabbits) and tail clipping (for mice) were developed to measure
-
Scottish Intercollegiate Guidelines Network Guidance on Dementia: The Investigation of Suspected Dementia (SIGN 168) with Focus on Biomarkers—Executive Summary Thromb. Haemost. (IF 5.0) Pub Date : 2024-06-11 Graham Andrew Mackay, Claire Gall, Ravi Jampana, Carolyn Sleith, Gregory Y. H. Lip, on behalf of the SIGN Dementia Guideline Development Group
This is an executive summary of the recent guidance produced by the Scottish Intercollegiate Guidelines Network (SIGN) dementia guideline group with regards to the investigation of suspected dementia. This is a sub-section of the broader SIGN 168 guideline released in November 2023. The guideline group included clinicians with expertise in Old Age Psychiatry, Neurology, Radiology, and Nuclear Medicine
-
Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec Thromb. Haemost. (IF 5.0) Pub Date : 2024-06-11 Debra D. Pittman, Charles Carrieri, Holly Soares, John McKay, Charles Y. Tan, John Z. Liang, Swapnil Rakhe, Jean-Claude Marshall, John E. Murphy, Puneet Gaitonde, Jeremy Rupon
Background Fidanacogene elaparvovec, an adeno-associated virus-based gene therapy vector expressing the high-activity factor IX (FIX) variant FIX-R338L, is in development for hemophilia B. One-stage clotting (OS) assays and chromogenic substrate (CS) assays are commonly used to measure FIX-R338L variant activity. Data from ongoing trials suggest FIX activity varies between different OS and CS assays
-
Genotype-Dependent Response to Desmopressin in Hemophilia A and Proposal of a Predictive Response Score Thromb. Haemost. (IF 5.0) Pub Date : 2024-06-11 Benoît Guillet, Maxime Pawlowski, Pierre Boisseau, Yohann Répessé, Philippe Beurrier, Sophie Bayart, Xavier Delavenne, Marc Trossaërt, Peter J. Lenting
Background Desmopressin (DDAVP) is used in patients with moderate/mild hemophilia A (PWMHs) to increase their factor VIII (FVIII) level and, if possible, normalize it. However, its effectiveness varies between individuals. The GIDEMHA study aims to investigate the influence of F8 gene variants. Material and Methods The study collected the trajectory of FVIII levels from therapeutic intravenous DDAVP
-
Anticoagulant Therapy in Pregnant Women with Mechanical Heart Valves: Italian Federation of Centers for Diagnosis and Surveillance of the Antithrombotic Therapies (FCSA) Position Paper Thromb. Haemost. (IF 5.0) Pub Date : 2024-06-01 Elena Campello, Paolo Bucciarelli, Filippo Catalani, Nicoletta Erba, Alessandro Squizzato, Daniela Poli, Scientific Reviewer Committee
The management of anticoagulant therapy in pregnant women with mechanical heart valves (MHVs) is difficult and often challenging even for clinicians experienced in the field. These pregnancies, indeed, are burdened with higher rates of complications for both the mother and the fetus, compared to those in women without MHVs. The maternal need for an optimal anticoagulation as provided by vitamin K antagonists
-
Are the Direct Oral Anticoagulants Better for Patients with Low Time in the Therapeutic Range on Vitamin K Antagonist Therapy? Thromb. Haemost. (IF 5.0) Pub Date : 2024-06-01 Jordan K Schaefer,Geoffrey D Barnes
-
Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2 Thromb. Haemost. (IF 5.0) Pub Date : 2024-05-24 Daisuke Sueta, Yugo Yamashita, Takeshi Morimoto, Ryuki Chatani, Yuji Nishimoto, Kazuhisa Kaneda, Nobutaka Ikeda, Yohei Kobayashi, Satoshi Ikeda, Kitae Kim, Moriaki Inoko, Toru Takase, Shuhei Tsuji, Maki Oi, Takuma Takada, Kazunori Otsui, Jiro Sakamoto, Yoshito Ogihara, Takeshi Inoue, Shunsuke Usami, Po-Min Chen, Kiyonori Togi, Norimichi Koitabashi, Seiichi Hiramori, Kosuke Doi, Hiroshi Mabuchi, Yoshiaki
Background Real-world data on clinical characteristics and outcomes related to the use of different direct oral anticoagulants (DOACs) for cancer-associated venous thromboembolism (VTE) is lacking. Methods The COMMAND VTE Registry-2 is a multicenter registry enrolling 5,197 consecutive patients with acute symptomatic VTE from 31 centers in Japan from January 2015 to August 2020. Our study population
-
Optimizing Use of High-Sensitivity Troponin for Risk-Stratification of Acute Pulmonary Embolism Thromb. Haemost. (IF 5.0) Pub Date : 2024-05-24 Sayhaan R. Goraya, Connor O'Hare, Kelsey A. Grace, William J. Schaeffer, S. Nabeel Hyder, Geoffrey D. Barnes, Colin F. Greineder
Background High-sensitivity troponin T (HS-TnT) may improve risk-stratification in hemodynamically stable acute pulmonary embolism (PE), but an optimal strategy for combining this biomarker with clinical risk-stratification tools has not been determined. Study Hypothesis We hypothesized that different HS-TnT cutoff values may be optimal for identifying (1) low-risk patients who may be eligible for
-
Platelet Activation Is Upregulated in Cirrhotic Patients with Portal Vein Thrombosis Thromb. Haemost. (IF 5.0) Pub Date : 2024-05-24 Fazhi Zhao, Jingnuo Ding, Juanjuan Cui, Mingqing Zhu, Weifeng Zhao
Objective Platelet plays a key role in thrombosis formation, especially that the alteration of platelet function may influence the thrombosis development. This study aimed to investigate platelet function alterations in the formation of portal vein thrombosis (PVT) in cirrhosis. Methods Cirrhotic patients admitted to The First Affiliated Hospital of Soochow University between October 2021 and April
-
Exploring Causal Relationships between Circulating Inflammatory Proteins and Thromboangiitis Obliterans: A Mendelian Randomization Study Thromb. Haemost. (IF 5.0) Pub Date : 2024-05-24 Bihui Zhang, Rui He, Ziping Yao, Pengyu Li, Guochen Niu, Ziguang Yan, Yinghua Zou, Xiaoqiang Tong, Min Yang
Background Thromboangiitis obliterans (TAO) is a vascular condition characterized by poor prognosis and an unclear etiology. This study employs Mendelian randomization (MR) to investigate the causal impact of circulating inflammatory proteins on TAO. Methods In this MR analysis, summary statistics from a genome-wide association study meta-analysis of 91 inflammation-related proteins were integrated
-
The Association between Obstructive Sleep Apnea and Venous Thromboembolism: A Bidirectional Two-Sample Mendelian Randomization Study Thromb. Haemost. (IF 5.0) Pub Date : 2024-05-23 Zhihai Huang, Zhenzhen Zheng, Lingpin Pang, Kaili Fu, Junfen Cheng, Ming Zhong, Lingyue Song, Dingyu Guo, Qiaoyun Chen, Yanxi Li, Yongting Lv, Riken Chen, Xishi Sun
Background Despite previous observational studies linking obstructive sleep apnea (OSA) to venous thromboembolism (VTE), these findings remain controversial. This study aimed to explore the association between OSA and VTE, including pulmonary embolism (PE) and deep vein thrombosis (DVT), at a genetic level using a bidirectional two-sample Mendelian randomization (MR) analysis. Methods Utilizing summary-level
-
Lack of Formyl-peptide Receptor 1 Mitigates Atherosclerosis in Hyperlipidemic Mice. Thromb. Haemost. (IF 5.0) Pub Date : 2024-05-23 Yvonne Döring,Alexander Bender,Oliver Soehnlein
-
Exploring the Two-Way Link between Migraines and Venous Thromboembolism: A Bidirectional Two-Sample Mendelian Randomization Study Thromb. Haemost. (IF 5.0) Pub Date : 2024-05-20 Yang Wang, Xiaofang Hu, Xiaoqing Wang, Lili Li, Peng Lou, Zhaoxuan Liu
Background The objective of this study is to utilize Mendelian randomization to scrutinize the mutual causality between migraine and venous thromboembolism (VTE) thereby addressing the heterogeneity and inconsistency that were observed in prior observational studies concerning the potential interrelation of the two conditions. Methods Employing a bidirectional Mendelian randomization approach, the
-
Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia Thromb. Haemost. (IF 5.0) Pub Date : 2024-05-17 Anna Ruiz-Llobet, Susanna Gassiot, Edurne Sarrate, Josune Zubicaray, Susana Rives, Warda Suleman, Rubén Berrueco
Background Venous thromboembolism (VTE) etiology in children with acute lymphoblastic leukemia (ALL) is multifactorial. The use of global assays of hemostasis as a thrombin generation test (TGT) is useful to individualize VTE risk in adult patients. This prospective cohort study aimed to evaluate the usefulness of an automated TGT to evaluate VTE risk during ALL treatment in children. Methods TGT (automated
-
Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice Thromb. Haemost. (IF 5.0) Pub Date : 2024-05-15 Kazuki Shimizu, Yuto Nakajima, Eisuke Takami, Hirotoshi Nakano, Keiji Nogami
Background Bypassing agents are used for breakthrough bleedings in patients with hemophilia A with inhibitor (PwHAwI) receiving emicizumab prophylaxis. Previous study demonstrated a weak binding affinity between emicizumab and factor (F)X (K d; 1.85 μM), and that this value was much greater than the plasma FX concentration (∼130 nM). We speculated that increased FX levels could enhance coagulation
-
Multi-phased Kinetics and Interaction of Protein Kinase Signaling in Glycoprotein VI-Induced Platelet αIIbβ3 Integrin Activation and Degranulation Thromb. Haemost. (IF 5.0) Pub Date : 2024-05-15 Pengyu Zhang, Saskia von Ungern-Sternberg, Luisa Hastenplug, Fiorella A. Solari, Albert Sickmann, Marijke J. E. Kuijpers, Johan W. M. Heemskerk, Ulrich Walter, Kerstin Jurk
Background Platelet glycoprotein VI (GPVI) stimulation activates the tyrosine kinases Syk and Btk, and the effector proteins phospholipase Cγ 2 (PLCγ2) and protein kinase C (PKC). Here, the activation sequence, crosstalk, and downstream effects of this Syk-Btk-PKC signalosome in human platelets were analyzed. Methods and Results Using immunoblotting, we quantified 14 regulated phospho-sites in platelets